Cxbladder is a genomic biomarker test designed to detect or safely rule out urothelial carcinoma in patients presenting with hematuria, and those being monitored for recurrence following treatment.

  • Enables risk stratification and safe rule out, reducing the need for further invasive procedures.
  • Resolves atypical cytology and equivocal cystoscopy, improving overall detection accuracy.
  • Offers a non-invasive surveillance alternative that can reduce the frequency of cystoscopy required in suitable patients, improving comfort and compliance.

Cxbladder works at a molecular level. The test combines clinical risk factor markers with genetic information, measuring five biomarker genes to detect the presence or absence of bladder cancer.

  • Reliable: Cxbladder delivers exceptional performance with 100% objectivity.
  • Clinically proven: Proven performance in over 20 peer-reviewed publications for risk stratification/ rule out, detection, and surveillance. Cxbladder has been trusted by over 2,000 urologists in more than 80,000 patients.
  • Covered by Medicare
  • Easy-to-use: Cxbladder’s unique urine sample collection system is discrete, non-invasive and easy-to-use.
  • In-home sampling: To streamline patient care we are now offering an in-home sampling service to both hematuria and surveillance patients.
  • Quick: Upon receiving a urine sample, our certified US laboratory will provide actionable results in 7 days.

Contact Us to Request More Information

A Suite of Tests Optimized to Primary Detection and Surveillance

Cxbladder comes as a suite of tests optimized to primary detection and bladder cancer surveillance.

Primary Detection

Cxbladder Triage

Designed for patients presenting with hematuria. Cxbladder Triage analyzes the presence of five biomarker genes alongside information on known bladder cancer risk factors like age, gender and smoking history to rule out patients with a low risk of having the disease.

Cxbladder Triage provides accurate results and reassurance that can reduce the need for further invasive procedures.

Cxbladder Detect

In cases where a patient is symptomatic and bladder cancer looks likely, Cxbladder Detect can help confirm your diagnosis. 

By detecting and quantifying signs of cancer at the molecular level, Cxbladder Detect outperforms other urine-based tests, making it an ideal choice for bladder cancer testing when patients present with significant symptoms. Cxbladder Detect can be used as an adjunct to cystoscopy or as a substitute for other radiological tests to improve overall detection accuracy. The test can also provide certainty when other procedures and tests are inconclusive. Cxbladder Detect is proven to adjudicate atypical cytology and equivocal cystoscopy. 

Bladder Cancer Surveillance

Cxbladder Monitor

Developed specifically for patients undergoing surveillance for recurrent bladder cancer. The test combines clinical information linked to previous bladder cancer with measured biomarker genes to help rule out the presence of a recurrent tumour, or to indicate that further clinical investigation is required.

Cxbladder Monitor can provide accurate results with a single urine sample, and test is often used as a non-invasive monitoring alternative to reduce the need for frequent cystoscopies.

Contact Us to Learn More About Triage, Detection, and Monitor

Featured audio: Bladder Cancer Matters Podcast: How COVID Changed How Bladder Cancer Doctors and Patients Interact. Sept, 2022. Sima Porten, MD (UCSF) and Bladder Cancer Matters Host, Rick Bangs (BCAN) discuss how COVID has changed the way bladder cancer doctors and patients interact. 

Grand Rounds in Urology: Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer. May, 2021. Sia Daneshmand, MD (Keck School of Medicine, USC), leads discussion with Sima Porten, MD (UCSF), and Anne Schuckman, MD (USC).

Featured study: Chu C, Li K, Meng M, Porten S. PD63-12: Use of Cxbladder Monitor during the COVID-19 Pandemic to reduce the frequency of surveillance cystoscopy. J Urol 2021; 206(3):1142e [abstract available]

Cxbladder In-Home Sampling is Available

Cxbladder’s unique urine sampling system is non-invasive and easy-to-use. The process is quick and painless, taking only minutes.

To simplify and streamline the bladder cancer testing process, we are now offering the Cxbladder In-Home Sampling Program for surveillance patients and those presenting with hematuria across the US. Participating patients have the option of submitting their urine sample in the comfort of their own home without the need to physically visit their Urologist.
Learn More

Cxbladder is Now Covered by Medicare

We’re pleased to confirm that Cxbladder is now covered by Medicare. For questions about coverage please call the Cxbladder Assist Team at 1-855-CXBLADR (1-855-292-5237, option 1).

Greater Confidence in the Diagnosis of Urothelial Carcinoma

Cxbladder is a reliable test for urothelial carcinoma that can help you make informed treatment and care decisions.

Most symptomatic or surveillance patients do not have bladder cancer. Cxbladder enables the accurate rule out of patients with hematuria and those being monitored for recurrence, reducing the burden of cystoscopy and sparing patients anxiety and discomfort. The test also solves a diagnostic dilemma, accurately resolving atypical cytology and inconclusive cystoscopy in the evaluation of patients presenting with hematuria or being monitored for recurrence.
Contact Us to Request More Information


Last Updated: 18 Jan 2023 02:19 pm

  • References

    Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).

Diagnosing bladder cancer

Drs Sia Daneshmand and Joseph DiTrolio discuss the guidelines, issues and technologies for diagnosing UC in patients presenting with hematuria in primary care.

Diagnosing bladder cancer
Diagnosing bladder cancer